Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT07406620

Entropy-based Physiological Signal Analysis in Patients With Obstructive Sleep Apnoea

Entropy-based Physiological Signal Analysis in Patients With Obstructive Sleep Apnoea — Active Not Recruiting • NCT07406620.

📅 08 Jul 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT07406620
Start
2026-06-11
Completion
2026-08
ClinicaliQ Trial Snapshot
  • Entropy-based Physiological Signal Analysis in Patients With Obstructive Sleep Apnoea — Active Not Recruiting • NCT07406620.
  • Study examines whether CPAP therapy reduces physiological signal complexity in obstructive sleep apnoea patients over six months.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This observational study is being undertaken as a part of a Master of Research (MRes) in Clinical Research programme. Its goal is to learn about how continuous positive airway pressure (CPAP) therapy changes the complexity of body signals in adults with obstructive sleep apnoea (OSA). The main question it aims to answer is: - How does the complexity of physiological signals (specifically oxygen saturation, heart rate, and heart rate variability) change in adults with OSA from before to after three and six months of CPAP treatment? It will use data…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn